+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intravenous Immunoglobulin Market - Global Forecast 2026-2032- Product Image
Intravenous Immunoglobulin Market - Global Forecast 2026-2032- Product Image
Sale

Intravenous Immunoglobulin Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889544
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Intravenous Immunoglobulin Market is projected to reach USD 15.42 Billion in 2026. It is expected to continue growing at a CAGR of 7.72%, reaching USD 24.15 Billion by 2032.

Intravenous Immunoglobulin: Executive Overview

Intravenous immunoglobulin (IVIG) is a plasma-derived therapy used to provide immune support or modulate abnormal immune responses. Its clinical role spans primary and secondary immunodeficiencies, autoimmune and inflammatory disorders, selected neurological conditions, and certain hematological applications. The market is shaped by clinical guidelines, plasma collection capacity, manufacturing complexity, product stewardship, reimbursement, and the need for reliable administration infrastructure.

Supply Resilience and Clinical Stewardship Are Reshaping IVIG

The IVIG landscape is being transformed by closer coordination between plasma collection, fractionation, quality control, logistics, and hospital pharmacy services. Because production depends on human plasma and involves stringent pathogen-safety controls, supply continuity remains a strategic concern. Health systems are also emphasizing evidence-based indications, dose optimization, alternatives where clinically appropriate, and monitoring of utilization. These shifts encourage more disciplined allocation without compromising access for patients with well-established treatment needs.

Artificial Intelligence Strengthens Forecasting, Safety, and Patient Management

Artificial intelligence can support IVIG delivery by improving demand planning, identifying unusual utilization patterns, assisting adverse-event surveillance, and helping clinicians synthesize patient histories and laboratory results. Machine-learning tools may also aid inventory prioritization and scheduling in settings where supply is constrained. However, responsible adoption requires validated datasets, explainable outputs, privacy safeguards, human oversight, and careful evaluation for bias. AI should complement-not replace-specialist judgment, clinical guidelines, pharmacovigilance, or regulatory requirements.

Regional Insights: Diverse Access Models Require Locally Adapted Strategies

North America combines advanced specialty-care infrastructure with strong attention to utilization management, plasma collection, and reimbursement controls. Europe, including the European Union, emphasizes coordinated safety standards, national procurement, and stewardship, while individual countries retain important differences in funding and clinical practice. Asia-Pacific presents varied maturity across Australia, China, India, Japan, and South Korea, with priorities spanning domestic plasma capacity, manufacturing capability, access, and specialist training. Latin America, represented by Brazil and Mexico, continues to balance public-sector access, procurement efficiency, and supply resilience. The Middle East, including GCC markets, is characterized by concentrated specialist services and strategic interest in dependable imports, local capability, and centralized purchasing. Africa faces wider variation in diagnostic access, infusion infrastructure, financing, and cold-chain reliability, making partnerships and workforce development particularly important.

Group Insights: Trade Blocs and Alliances Influence Coordination

ASEAN countries are connected by regional supply-chain and regulatory cooperation but retain distinct health financing and approval systems. BRICS members bring diverse approaches to domestic manufacturing, public procurement, plasma policy, and technology transfer. The European Union supports alignment through shared regulatory principles while preserving national reimbursement decisions. G7 members generally have mature specialty-care systems and strong pharmacovigilance expectations, but still face pressure to improve resilience and affordability. GCC countries can leverage coordinated procurement and centralized health networks to strengthen access. NATO members span varied health systems, yet cooperation on preparedness, logistics, and continuity planning can support resilience during disruptions.

Country Insights: Policy, Infrastructure, and Clinical Capacity Drive Differences

Australia relies on coordinated health-system planning and specialist services while maintaining close attention to plasma stewardship. Brazil and Mexico must align public access, procurement, distribution, and domestic capability across geographically diverse systems. Canada and the United States combine sophisticated immunology and neurology services with active management of supply and reimbursement. China and India are strengthening local healthcare and biopharmaceutical capabilities while addressing substantial regional variation in access. France, Germany, Italy, Spain, and the United Kingdom operate within mature clinical environments, with differences in procurement, reimbursement, guidelines, and national supply priorities. Japan and South Korea emphasize quality, specialist oversight, and reliable delivery within advanced healthcare systems. Russia’s access environment is influenced by domestic production, procurement structures, and broader supply-chain considerations.

Action Priorities for IVIG Industry Leaders

Leaders should diversify and transparently manage plasma and manufacturing inputs, strengthen supplier qualification, and maintain contingency plans for logistics and critical materials. Clinical value can be improved through indication-based protocols, dose and duration review, outcome tracking, and collaboration with professional societies and hospitals. Organizations should invest in pharmacovigilance, traceability, cold-chain monitoring, and digital inventory tools, while applying AI only through controlled validation and governance. Regional strategies should reflect local regulatory, reimbursement, procurement, and infrastructure conditions. Patient and clinician education is also essential to support appropriate use, shared decisions, and timely recognition of adverse reactions.

Research Methodology: Evidence-Based Market Dimension Analysis

This executive summary uses the specified IVIG market dimension and the required regional, group, and country coverage as its analytical frame. The assessment synthesizes established considerations in clinical use, plasma-derived biologics manufacturing, supply-chain management, healthcare delivery, regulation, reimbursement, and digital transformation. Insights are presented qualitatively and avoid estimates, forecasts, market shares, and company-specific claims. Regional and country comparisons reflect structural differences in health-system capacity, procurement, access, clinical specialization, and policy environments; conclusions should be validated against current local guidelines and official health-agency sources before operational decisions are made.

Conclusion: Resilience and Appropriate Use Define Sustainable Progress

IVIG remains a clinically important therapy whose value depends on dependable supply, rigorous safety systems, and appropriate patient selection. The most durable progress will come from integrating plasma stewardship, manufacturing resilience, evidence-based clinical pathways, equitable procurement, and accountable digital tools. Because conditions differ substantially across regions, groups, and countries, leaders should combine common quality principles with locally tailored access and implementation strategies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Intravenous Immunoglobulin Market, by Product Type
7.1. Introduction
7.2. High Purity Immunoglobulin
7.3. Normal Immunoglobulin
7.3.1. Liquid
7.3.2. Lyophilized
8. Intravenous Immunoglobulin Market, by Patient Type
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Intravenous Immunoglobulin Market, by Indication
9.1. Introduction
9.2. Autoimmune Diseases
9.2.1. Guillain-Barré Syndrome
9.2.2. Immune Thrombocytopenic Purpura
9.2.3. Kawasaki Disease
9.3. Hematological Conditions
9.4. Immunodeficiency Disorders
9.4.1. Primary Immunodeficiency
9.4.2. Secondary Immunodeficiency
9.5. Neurological Disorders
9.5.1. Chronic Inflammatory Demyelinating Polyneuropathy
9.5.2. Multifocal Motor Neuropathy
10. Intravenous Immunoglobulin Market, by End User
10.1. Introduction
10.2. Home Care
10.3. Hospital
10.3.1. Private Hospital
10.3.2. Public Hospital
10.4. Specialty Clinic
10.4.1. Hematology Clinic
10.4.2. Immunology Clinic
10.4.3. Neurology Clinic
11. Intravenous Immunoglobulin Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Intravenous Immunoglobulin Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Intravenous Immunoglobulin Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Intravenous Immunoglobulin Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ADMA Biologics, Inc.
16.2. Baxter International Inc.
16.3. Bayer Aktiengesellschaft
16.4. Biological E. Limited
16.5. CSL Behring LLC
16.6. Emergent BioSolutions Inc.
16.7. GC Biopharma Corp.
16.8. Grifols, S.A.
16.9. Guangdong Shuanglin Bio-Pharmacy Co., Ltd.
16.10. Hualan Biological Engineering, Inc.
16.11. Intas Pharmaceuticals Limited
16.12. Kamada Ltd.
16.13. Octapharma AG
16.14. Panacea Biotec Limited
16.15. Pfizer Inc.
16.16. Sanquin Plasma Products B.V.
16.17. Takeda Pharmaceutical Company Limited
16.18. Top Bio Group Co., Ltd.
16.19. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Intravenous Immunoglobulin Market, Years Considered for the Study
FIGURE 2. Global Intravenous Immunoglobulin Market, Research Design
FIGURE 3. Global Intravenous Immunoglobulin Market, Research Framework
FIGURE 4. Global Intravenous Immunoglobulin Market, Data Triangulation
FIGURE 5. Global Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Intravenous Immunoglobulin Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Intravenous Immunoglobulin Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Intravenous Immunoglobulin Market Size, by Patient Type, 2025 vs 2032 (%)
FIGURE 9. Global Intravenous Immunoglobulin Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Intravenous Immunoglobulin Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Intravenous Immunoglobulin Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Intravenous Immunoglobulin Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Intravenous Immunoglobulin Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Intravenous Immunoglobulin Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Intravenous Immunoglobulin Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Intravenous Immunoglobulin Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Intravenous Immunoglobulin Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Intravenous Immunoglobulin Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Intravenous Immunoglobulin Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Intravenous Immunoglobulin Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Intravenous Immunoglobulin Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Intravenous Immunoglobulin Market Segmentation & Coverage
TABLE 2. Global Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 3. Global Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global High Purity Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global High Purity Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global High Purity Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Normal Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Normal Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Normal Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Lyophilized Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Lyophilized Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Lyophilized Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 17. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 27. Global Autoimmune Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Autoimmune Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Autoimmune Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Guillain-Barré Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Guillain-Barré Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Guillain-Barré Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Immune Thrombocytopenic Purpura Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Immune Thrombocytopenic Purpura Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Immune Thrombocytopenic Purpura Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Kawasaki Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Kawasaki Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Kawasaki Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Hematological Conditions Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Hematological Conditions Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Hematological Conditions Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Immunodeficiency Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Immunodeficiency Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Immunodeficiency Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Primary Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Primary Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Primary Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Secondary Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Secondary Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Secondary Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Chronic Inflammatory Demyelinating Polyneuropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Chronic Inflammatory Demyelinating Polyneuropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Chronic Inflammatory Demyelinating Polyneuropathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Multifocal Motor Neuropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Multifocal Motor Neuropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Multifocal Motor Neuropathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Public Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Public Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Public Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Hematology Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Hematology Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Hematology Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Immunology Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Immunology Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Immunology Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Neurology Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Neurology Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Neurology Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Intravenous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Intravenous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. North America Intravenous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. North America Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. North America Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 108. North America Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 109. North America Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. North America Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 111. North America Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 112. North America Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 113. North America Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. North America Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 115. North America Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 116. North America Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Latin America Intravenous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Latin America Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 119. Latin America Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 120. Latin America Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 121. Latin America Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. Latin America Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 123. Latin America Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 124. Latin America Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 125. Latin America Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. Latin America Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 127. Latin America Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 128. Latin America Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Europe Intravenous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Europe Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 131. Europe Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 132. Europe Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 133. Europe Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. Europe Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 135. Europe Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 136. Europe Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 137. Europe Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Europe Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 139. Europe Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 140. Europe Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. Middle East Intravenous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Middle East Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 143. Middle East Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 144. Middle East Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 145. Middle East Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 146. Middle East Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 147. Middle East Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 148. Middle East Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 149. Middle East Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Middle East Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 151. Middle East Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 152. Middle East Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. Africa Intravenous Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Africa Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 155. Africa Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 156. Africa Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 157. Africa Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. Africa Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 159. Africa Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 160. Africa Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 161. Africa Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. Africa Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 163. Africa Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 164. Africa Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. Global Intravenous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. ASEAN Intravenous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. ASEAN Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. ASEAN Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 169. ASEAN Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 170. ASEAN Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. ASEAN Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 172. ASEAN Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 173. ASEAN Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 174. ASEAN Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. ASEAN Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 176. ASEAN Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 177. ASEAN Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. GCC Intravenous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. GCC Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. GCC Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 181. GCC Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 182. GCC Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 183. GCC Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 184. GCC Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 185. GCC Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 186. GCC Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. GCC Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 188. GCC Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 189. GCC Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. European Union Intravenous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. European Union Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 192. European Union Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 193. European Union Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 194. European Union Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. European Union Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 196. European Union Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 197. European Union Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 198. European Union Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. European Union Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 200. European Union Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 201. European Union Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. BRICS Intravenous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 203. BRICS Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 204. BRICS Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 205. BRICS Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 206. BRICS Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 207. BRICS Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 208. BRICS Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 209. BRICS Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 210. BRICS Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. BRICS Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 212. BRICS Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 213. BRICS Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. G7 Intravenous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. G7 Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 216. G7 Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 217. G7 Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 218. G7 Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. G7 Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 220. G7 Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 221. G7 Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 222. G7 Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. G7 Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 224. G7 Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 225. G7 Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. NATO Intravenous Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 227. NATO Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 228. NATO Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 229. NATO Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 230. NATO Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 231. NATO Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 232. NATO Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 233. NATO Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 234. NATO Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. NATO Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 236. NATO Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 237. NATO Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. Global Intravenous Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 239. United States Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 240. United States Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 241. United States Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 242. United States Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 243. United States Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. United States Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 245. United States Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 246. United States Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 247. United States Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. United States Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 249. United States Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 250. United States Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Canada Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 252. Canada Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 253. Canada Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 254. Canada Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 255. Canada Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 256. Canada Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 257. Canada Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 258. Canada Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 259. Canada Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. Canada Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 261. Canada Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 262. Canada Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Mexico Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 264. Mexico Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 265. Mexico Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 266. Mexico Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 267. Mexico Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. Mexico Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 269. Mexico Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 270. Mexico Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 271. Mexico Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Mexico Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 273. Mexico Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 274. Mexico Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 275. Brazil Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 276. Brazil Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 277. Brazil Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 278. Brazil Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 279. Brazil Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 280. Brazil Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 281. Brazil Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 282. Brazil Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 283. Brazil Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. Brazil Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 285. Brazil Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 286. Brazil Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 287. United Kingdom Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 288. United Kingdom Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 289. United Kingdom Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 290. United Kingdom Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 291. United Kingdom Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 292. United Kingdom Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 293. United Kingdom Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 294. United Kingdom Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 295. United Kingdom Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. United Kingdom Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 297. United Kingdom Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 298. United Kingdom Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Germany Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 300. Germany Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 301. Germany Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 302. Germany Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 303. Germany Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 304. Germany Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 305. Germany Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 306. Germany Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 307. Germany Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. Germany Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 309. Germany Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 310. Germany Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 311. France Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 312. France Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 313. France Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 314. France Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 315. France Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 316. France Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 317. France Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 318. France Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 319. France Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 320. France Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 321. France Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 322. France Intravenous Immunoglobulin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 323. Russia Intravenous Immunoglobulin Market Size, 2017-2032 (USD Million)
TABLE 324. Russia Intravenous Immunoglobulin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 325. Russia Intravenous Immunoglobulin Market Size, by Normal Immunoglobulin, 2017-2032 (USD Million)
TABLE 326. Russia Intravenous Immunoglobulin Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 327. Russia Intravenous Immunoglobulin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 328. Russia Intravenous Immunoglobulin Market Size, by Autoimmune Diseases, 2017-2032 (USD Million)
TABLE 329. Russia Intravenous Immunoglobulin Market Size, by Immunodeficiency Disorders, 2017-2032 (USD Million)
TABLE 330. Russia Intravenous Immunoglobulin Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 331. Russia Intravenous Immunoglobulin Market Size, by End User, 2017-2032 (USD Million)
TABLE 332. Russia Intravenous Immunoglobulin Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 333. Russia Intravenous Immunoglobulin Market Size, by Specialty Clinic, 2017-2032 (USD Million)
TABLE 334. Russia Intravenous Immunoglobulin Market Size, by Distribution

Companies Mentioned

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Bayer Aktiengesellschaft
  • Biological E. Limited
  • CSL Behring LLC
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • Grifols, S.A.
  • Guangdong Shuanglin Bio-Pharmacy Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • Intas Pharmaceuticals Limited
  • Kamada Ltd.
  • Octapharma AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanquin Plasma Products B.V.
  • Takeda Pharmaceutical Company Limited
  • Top Bio Group Co., Ltd.
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

Related Topics

Related Reports

Immunoglobulin Product Market - Global Forecast 2026-2032 - Product Image

Immunoglobulin Product Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report - Product Image

Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report

  • Report
  • 219 Pages
  • Global
From
Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 226 Pages
  • Global
From
Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2026-2034 - Product Image

Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2026-2034

  • Report
  • 136 Pages
  • Global
From
Intravenous Immunoglobulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Intravenous Immunoglobulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From

About the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is a subset of the biotechnology industry that focuses on the production and distribution of immunoglobulin products. IVIG is a blood product derived from the pooled plasma of healthy donors, and is used to treat a variety of conditions, including autoimmune diseases, infections, and immunodeficiencies. IVIG is also used in the prevention of certain infections in immunocompromised patients. IVIG is produced by a number of companies, including CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. These companies are involved in the production, distribution, and marketing of IVIG products. They also provide support services such as patient education, reimbursement assistance, and clinical trial support. Additionally, some companies are involved in the development of new IVIG products, such as recombinant immunoglobulins and monoclonal antibodies. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.